PER® Miami Breast Cancer Conference | Conference

Predictive, Prognostic Models May Tailor Neoadjuvant Approach in HER2+ Breast Cancer

March 3rd 2023

With the advent of effective drug regimens to treat HER2-positive breast cancer, the use of tailored efforts with neoadjuvant therapy in this space may continue to improve efficacy moving forward.

HER2-Low Expression is the Tip of the Iceberg in Breast Cancer Classification

March 3rd 2023

The advent of antibody-drug conjugates has placed a renewed focus on the lesser thought of HER2 classifications of IHC 1+ and 0.

Pilewskie Highlights Trends for Surgical Management of High-risk Breast Lesions

March 3rd 2023

Melissa L. Pilewskie, MD, highlightes some of the primary components of her presentation concerning high-risk breast lesions, which will be delivered during the 40th Annual Miami Breast Cancer Conference®

Dr. Esserman on the I-SPY2 Trial in Breast Cancer

March 3rd 2023

Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.

Miami Breast Cancer Conference Celebrates 40 Years

March 3rd 2023

The agenda set for this year's Miami Breast Cancer Conference® has been shaped by the recent updates out of the 2022 San Antonio Breast Cancer Symposium, updates to guideline recommendations over the past year, and the influence of new indications and approvals across subtypes of breast cancer.

Talazoparib Shows Real-World Clinical Benefit in Germline BRCA-Mutated, HER2-Negative, Advanced Breast Cancer

March 9th 2022

Clinical outcomes achieved with talazoparib in a real-world population of patients with HER2-negative, locally advanced or metastatic breast cancer harboring germline BRCA mutations proved to be consistent with those observed in the phase 3 EMBRACA trial.

Biomarkers Allow for Tailoring TNBC Treatments

March 5th 2022

Several factors aid treatment selection for patients with newly diagnosed metastatic triple-negative breast cancer, with upfront PD-L1 and BRCA testing being the most critical biomarkers to examine.

Abemaciclib/Endocrine Therapy Combo Showcases Long-Term Clinical Benefit in HR+ High-Risk Early Breast Cancer

March 5th 2022

The combination of adjuvant abemaciclib and endocrine therapy led to a clinically meaningful benefit at 3 years in patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer.

Addressing Cardiotoxicity in Breast Cancer Requires Multifaceted Approach

March 5th 2022

Clinicians with patients who are experiencing cardiotoxicity as a result of their breast cancer treatment should address the cardiotoxicity using a team-oriented approach based on guideline-directed therapies.

Elacestrant Significantly Improves PFS Over SOC in Advanced ER+ Metastatic Breast Cancer

March 5th 2022

Elacestrant was found to result in a statistically significant and clinically meaningful improvement in progression-free survival over standard-of-care treatment in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibitors.

Dr. Borgen on the Immuno-Oncology Clinical Trials in Breast Cancer

March 4th 2022

Patrick Borgen, MD, discusses the evolution of immuno-oncology clinical trials in breast cancer.

Dr. Tripathy on the Emergence of Genomics Research in Breast Cancer

March 4th 2022

Debu Tripathy, MD, discusses the emergence of genomics research in breast cancer.

Adjuvant CDK4/6 Inhibitors Demonstrate Success in Early-Stage HR+ Breast Cancer Development

March 4th 2022

CDK4/6 inhibitors in the metastatic setting have demonstrated clinical benefit in the hormone receptor–positive breast cancer population, leading to curiosity of its activity in early-stage patients and setting the stage for a handful of informative clinical trials.

Neoadjuvant Immunotherapy/Chemotherapy Combos Gain in Prominence for Early-Stage TNBC

March 4th 2022

Immunotherapy treatment for early-stage triple-negative breast cancer is enjoying a boom period, though there are still unanswered questions, particularly around the optimal chemotherapy backbone and patient selection.

Breast Cancer Research Begins With Curiosity

March 4th 2022

Getting a start in clinical research can appear daunting, said Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C). Fortunately, all it really takes is a question and a bit of drive.

ctDNA Assays Open the Door for Earlier Detection, Intervention in Breast Cancer

March 4th 2022

Pat W. Whitworth, MD, explains how data from past studies are informing the use of circulating tumor DNA and talks about the potential of these assays to guide treatment decisions in patients with breast cancer.

Loprinzi Shares Top Concerns, Best Practices for Treatment-Related Toxicity Management in Breast Cancer

March 4th 2022

Charles L. Loprinzi, MD, discusses some of the most common treatment-related toxicities in breast cancer and provided insight into various current and investigational approaches available to patients.

Chemoimmunotherapy Anchors Frontline Treatment in Metastatic TNBC

March 4th 2022

Patients with newly diagnosed metastatic triple-negative breast cancer should undergo PD-L1 expression testing on tumors to determine whether they are candidates for frontline chemoimmunotherapy.

Real-World Data Describe Eribulin Efficacy After Novel Agents for MBC

March 4th 2022

Treatment with eribulin elicited an estimated 2-year overall survival rate of 53.6% for patients with metastatic breast cancer previously treated with atezolizumab or sacituzumab govitecan, according to real-world findings.

Dr. Hurvitz on Utilizing CDK4/6 Inhibitors in HR+ Breast Cancer

March 4th 2022

Sara A. Hurvitz, MD, discusses utilizing CDK4/6 inhibitors in hormone receptor-positive breast cancer.